Page 3 - Vectr Ventures News Today

The economist Michael Porter once said that California is successful for its wine, not because of it...

With an infusion of $11.4 million in pre-series A funding announced today, Australian startup Provectus Algae is ready to rapidly scale the commercial production capacity of its sustainable and “complementary” biomanufacturing platform that leverages algae to develop a wide range of high-value ingredients, including a high-performance blood red colorant for the alternative protein market.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

ORIGYN Foundation, a Swiss-based non-profit organization that helps identify, authenticate, and unlock the power of owning valuable objects, has netted ORIGYN Foundation secures $20 million from investors like Paris Hilton and Bill Ackman.

ORIGYN Foundation valued at $300 million by exclusive set of investors in a select, private round to bring NFTs to life Strategic raise will launch ORIGYN Foundation's verticals to market in the art

GEORGE TOWN, Cayman Islands-Aries I Acquisition Corporation announced the appointments of Mr. Aaron Ratner and Mr. Paul Wolfe to the Board of Directors. Mr. Aaron Ratner,... | October 13, 2021

Engine Biosciences, Singapore- and San Carlos, CA-based company deciphering complex biology to create medicines , raised $43m in Series A funding round. The round was led by Polaris Partners qith participation from new investors Invus and one of the world’s premier institutional investors, based in Singapore, as well as existing investors 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio. Amy Schulman, Managing Partner at ...

SG-based Engine Biosciences raises $43m Series A led by Polaris Partners Jeffrey Lu, Co-Founder and CEO, Engine Biosciences. May 26, 2021 Singapore and Silicon Valley-based biotech firm Engine Biosciences on Wednesday announced it has raised $43 million (S$57 million) in a Series A round led by US-based healthcare and technology investor Polaris Partners. The round was joined by private equity firm Invus and an undisclosed institutional investor based in Singapore, the firm said in a statement....

Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series A funding round.

MedCity News Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, "deciphering biology" to find new cancer drugs. Shares0   Drug discovery startup Engine Biosciences has leveraged its computational technology into potential new drugs for itself and its pharmaceutical p...